Articles related to ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

Recognizing potential influences of sex hormones on ADHD symptoms in females may direct future therapies, specifically targeting the hormonal elements of ADHD exacerbations during phases such as menopause and the luteal phase of the menstrual cycle.

Triple-release dexmethylphenidate formulation demonstrated dose-dependent ADHD symptom improvements with effect sizes ranging from 0.737 to 1.185 across all tested doses in pediatric patients.

Clinical practice observations of AVN following hip injury where non-adherence to activity restrictions was a contributing factor highlight the intersection of medication effects and behavioral challenges in ADHD patients.

Clinical trials demonstrate bupropion effectiveness at 150-450mg daily for ADHD symptom reduction, with extended-release formulations improving medication adherence through once-daily dosing.

Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.

Methylphenidate significantly improved participants’ driving performance by reducing lane weaving and speed variation.